SCHEMBL12595865

SCHEMBL12595865

Cc1cc(-c2ccc(=O)[nH]n2)ccc1N1CCC(O)C1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAD52 P43351 1/20 0.44
▸ LMNA P02545 2/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ PDE4A P27815 1/20 0.41
▸ PDE4B Q07343 1/20 0.41
▸ PDE4C Q08493 1/20 0.41
▸ PDE4D Q08499 1/20 0.41
▸ HRH3 Q9Y5N1 7/20 0.40
▸ PDE3B Q13370 3/20 0.40
▸ PDE3A Q14432 3/20 0.40
▸ PIM1 P11309 3/20 0.40
▸ KCNH2 Q12809 2/20 0.39
▸ CLK2 P49760 1/20 0.39
▸ CLK3 P49761 1/20 0.39
▸ DYRK1A Q13627 1/20 0.39
▸ CHRM2 P08172 1/20 0.38
▸ SLC6A2 P23975 1/20 0.38
▸ ADRA1A P35348 1/20 0.38
▸ HTR3A P46098 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12595767 0.94 LMNA (0.47) LMNAMEN1KMT2APDE4APDE4B
SCHEMBL12595850 0.93 HRH3 (0.43) RAD52LMNAMEN1KMT2APDE4A
SCHEMBL12595849 0.91 LMNA (0.48) LMNAMEN1KMT2APDE4APDE4B
SCHEMBL12595902 0.84 LMNA (0.42) LMNAMEN1KMT2APDE4APDE4B
SCHEMBL12595917 0.84 LMNA (0.42) LMNAMEN1KMT2APDE4APDE4B
SCHEMBL13071049 0.84 PDE3B (0.59) PDE3BPDE3A
SCHEMBL12595842 0.82 HRH3 (0.43) LMNAMEN1KMT2APDE4APDE4B
SCHEMBL12595898 0.82 LMNA (0.44) LMNAMEN1KMT2APDE4APDE4B
SCHEMBL12595915 0.82 LMNA (0.44) LMNAMEN1KMT2APDE4APDE4B
SCHEMBL12595816 0.82 LMNA (0.51) LMNAMEN1KMT2APDE4APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8501731-B2 Derivatives of 6[3-(trifluoromethyl)phenyl]pyridazin-3(2H)-one having antitumor activity SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2013-08-06 — — US disclosed
US-20110112061-A1 PYRIDAZINONES, THE PREPARATION AND THE USE THEREOF SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2011-05-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112061-A1 PYRIDAZINONES, THE PREPARATION AND THE USE THEREOF PDXK, PNPO, HCCS RAD52 1512/4885LMNA 109/4885MEN1 424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback